Back to Journals » Clinical Interventions in Aging » Volume 4

A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis

Authors Karagiannis D, Georgalas I, Ladas I, Eustratios P, Mitropoulos P

Published 22 December 2008 Volume 2009:4 Pages 63—65

DOI https://doi.org/10.2147/CIA.S4803

Review by Single-blind

Peer reviewer comments 4


Dimitrios Karagiannis1, Ilias Georgalas2, Ioannis Ladas2, Parikakis Eustratios1, Panagiotis Mitropoulos1

1Second Department of Ophthalmiatrion Eye Hospital, NHS, Athens, Greece; 2Department of Ophthalmology, “G.Genimatas” General Hospital, Athens, Greece

Abstract: A 65-year-old lady presented with decreased vision in her left eye (LE). Best corrected visual acuity (BCVA) was 1/20. Complete examination showed idiopathic juxtafoveal retinal telangiectasis associated with subretinal neovascularization and she was treated with intravitreal ranibizumab every month for three months in the LE. After four months, her BCVA increased to 3/10. Fluorescein angiography (FA) showed minimal leakage and optical coherence tomography (OCT) confirmed absence of intra- or subretinal fluid in the macula. Examinations were repeated monthly for another 12 months and showed no recurrence. Intravitreal ranibizumab showed promising results for subretinal neovascularization due to idiopathic juxtafoveal retinal telangiectasis. A prospective study with large series of patients and controls may be necessary in order to determine the effectiveness of this treatment.

Keywords: idiopathic juxtafoveal retinal telangiectasis, ranibizumab, subretinal neovascularization

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]